

an Open Access Journal by MDPI

Cancer Targeted Gene and Drug Delivery Nanosystems

Guest Editor:

Dr. Henrique Faneca

Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal

Deadline for manuscript submissions:

closed (30 April 2024)

Message from the Guest Editor

Dear Colleagues,

Nanotechnology-based systems have shown that they can greatly contribute to the development of novel and successful antitumor strategies, offering higher therapeutic efficacy and fewer side effects than conventional approaches. In fact, targeted nanosystems, have the ability to both passively (in the case of solid tumors) and actively accumulate in tumors, due to the enhanced permeation and retention (EPR) effect and the incorporation of target moieties in nanocarriers, respectively. Thus, targeted nanosystems may allow the specific delivery of therapeutic agents in target cells, avoiding their release in the nontarget ones. Moreover, nanosystems facilitate the of innovative multitarget therapeutic development strategies in a single nanoplatform, allowing the specific and simultaneous delivery of different therapeutic agents in target cells, increasing antitumor efficiency and reducing secondary effects.

This Special Issue aims to highlight the recent developments in cancer-targeted genes and drug delivery nanosystems. Original papers or reviews on the design, development, characterization, and application of drug and/or gene delivery nanosystems are welcome.







IMPACT FACTOR 4.9





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us